Oppenheimer & Co. Inc. Has $5.33 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

Oppenheimer & Co. Inc. lowered its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 20.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,887 shares of the life sciences company’s stock after selling 10,424 shares during the period. Oppenheimer & Co. Inc.’s holdings in Illumina were worth $5,332,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mengis Capital Management Inc. acquired a new stake in shares of Illumina during the 3rd quarter valued at about $1,221,000. Platform Technology Partners lifted its stake in Illumina by 4.2% during the third quarter. Platform Technology Partners now owns 3,512 shares of the life sciences company’s stock worth $458,000 after purchasing an additional 141 shares during the period. Entropy Technologies LP acquired a new stake in Illumina during the third quarter valued at approximately $1,378,000. Venturi Wealth Management LLC boosted its holdings in Illumina by 18.9% during the third quarter. Venturi Wealth Management LLC now owns 2,650 shares of the life sciences company’s stock valued at $346,000 after purchasing an additional 422 shares in the last quarter. Finally, Weil Company Inc. grew its stake in shares of Illumina by 10.2% in the 3rd quarter. Weil Company Inc. now owns 21,144 shares of the life sciences company’s stock valued at $2,757,000 after purchasing an additional 1,952 shares during the period. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the company. Daiwa Capital Markets raised Illumina from a “neutral” rating to a “buy” rating and boosted their price target for the company from $120.00 to $154.00 in a research note on Friday, August 16th. Leerink Partners boosted their target price on shares of Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Stephens increased their target price on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday. Royal Bank of Canada boosted their price target on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Finally, Robert W. Baird upped their price objective on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and a consensus price target of $164.00.

Illumina Stock Down 2.7 %

Shares of NASDAQ ILMN opened at $142.24 on Friday. Illumina, Inc. has a 1 year low of $92.69 and a 1 year high of $156.66. The firm’s 50-day moving average is $139.20 and its 200-day moving average is $124.10. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $22.56 billion, a PE ratio of -14.28 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same period last year, the firm earned $0.33 earnings per share. Equities analysts expect that Illumina, Inc. will post 4.11 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.